<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122221</url>
  </required_header>
  <id_info>
    <org_study_id>CRTE7A2-2107C</org_study_id>
    <nct_id>NCT05122221</nct_id>
  </id_info>
  <brief_title>CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of CRTE7A2-01 TCR-T Cell for HPV16 Positive Advanced Cervical, Anal, or Head and Neck Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corregene Biotechnology Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corregene Biotechnology Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, open, single arm dose escalation phase I study to evaluate the safety,&#xD;
      tolerability, and efficacy of CRTE7A2-01 TCR-T cell for HPV16 positive advanced cervical,&#xD;
      anal, or head and neck cancers. The study will determine MTD of CRTE7A2-01 TCR-T cell&#xD;
      injection, as well as investigate RP2D.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>28 days</time_frame>
    <description>Maximum Tolerated Dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>28 days</time_frame>
    <description>Dose-limiting toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D</measure>
    <time_frame>28 days</time_frame>
    <description>Recommended Phase II Dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment related AEs, AEs of special interest and serious adverse events (SAEs).</measure>
    <time_frame>2 years</time_frame>
    <description>grade 1-5 (CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate（ORR）</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate（DCR）</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response（DOR）</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival（PFS）</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by RECIST 1.1</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peripheral blood TCR-T cell copy number</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Negative conversion rate among HPV-16 positive patients detected by tissue biopsy</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Anal Cancer</condition>
  <condition>Head and Neck Cancers</condition>
  <arm_group>
    <arm_group_label>CRTE7A2-01 TCR-T cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo lymphocytapheresis, then treatment with TCR-T cell (at escalating doses) + IL-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine + Cyclophosphamide</intervention_name>
    <description>Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 500mg/m²/day×3 days</description>
    <arm_group_label>CRTE7A2-01 TCR-T cell therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>Interleukin-2 20,000,000 IU/time infused within 15 minutes approximately every 8 hours (according to the subject's tolerance, the interval between medications can be extended to 24 hours) for a maximum usage time up to 14 days.</description>
    <arm_group_label>CRTE7A2-01 TCR-T cell therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CRTE7A2-01 TCR-T Cell</intervention_name>
    <description>On day 0, the TCR-T cells will be administered one time, each bag of cell intravenously within 20 minutes.</description>
    <arm_group_label>CRTE7A2-01 TCR-T cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years and ≤65 years.&#xD;
&#xD;
          2. Histologically-confirmed cervical cancer, anal cancer, head and neck cancers with&#xD;
             confirmed HPV16 infection and HLA-A*02:01 allele&#xD;
&#xD;
          3. Failure on or intolerance to systemic therapy for unresectable advanced cancer.&#xD;
&#xD;
          4. ECOG performance status of 0-1.&#xD;
&#xD;
          5. Estimated life expectancy ≥ 3 months.&#xD;
&#xD;
          6. Patients must have at least one measurable lesion defined by RECIST 1.1.&#xD;
&#xD;
          7. Female patients of childbearing age must undergo a serum pregnancy test within 7 days&#xD;
             prior to study treatment and the results must be negative, and are willing to use a&#xD;
             very effective and reliable method of contraception from screening through 6 months&#xD;
             after the last dose of study treatment.&#xD;
&#xD;
          8. The patient must be willing to sign the informed consent form and have a good&#xD;
             anticipation of compliance with study procedure.&#xD;
&#xD;
        Exclusion Criteria：&#xD;
&#xD;
          1. The proportion of T cell immune-related gene deletion mutations&gt;5%.&#xD;
&#xD;
          2. Patient received any genetically modified T cell therapy.&#xD;
&#xD;
          3. Patient who is being treated with T cell immunosuppressive agent （such as&#xD;
             cyclophosphamide, FK506,tripterygium glycosides） or T cell immunoagonist.&#xD;
&#xD;
          4. Patients received chemotherapy, targeted therapy, immunotherapy, or other&#xD;
             investigational agents within 2 weeks and received radiotherapy within 4 weeks before&#xD;
             apheresis.&#xD;
&#xD;
          5. Patients with any organ dysfuntion as defined below:&#xD;
&#xD;
               -  leukocytes&lt;3.0 x 109/L&#xD;
&#xD;
               -  absolute neutrophil count &gt;1.5 x 109/L&#xD;
&#xD;
               -  hemoglobin&lt;90g/L&#xD;
&#xD;
               -  platelets &lt;100 x 1010/L&#xD;
&#xD;
               -  lymphocytes&lt;0.8 x 109/L&#xD;
&#xD;
               -  percentage of lymphocytes&lt;15%&#xD;
&#xD;
               -  creatinine&gt;1.5×ULN or creatinine clearance &lt;50mL/min&#xD;
&#xD;
               -  total bilirubin&gt;3×ULN; ALT/AST&gt;3×ULN (patients with liver metastasis,&gt;5×ULN)&#xD;
&#xD;
               -  INR&gt;1.5×ULN; APTT&gt;1.5×ULN&#xD;
&#xD;
               -  SpO2≤90%&#xD;
&#xD;
          6. Patients with serious medical conditions, disorders, and / or comorbidities,&#xD;
             including, but are not limited to: severe heart disease, cerebrovascular disease,&#xD;
             epileptic seizures, uncontrolled diabetes (CTCAE 5.0: FBG ≥ 2 grade), active&#xD;
             infection, active digestive tract Ulcer, gastrointestinal bleeding, intestinal&#xD;
             obstruction, pulmonary fibrosis, renal failure, respiratory failure.&#xD;
&#xD;
          7. Patient with a severe cardiovascular disease with 6 months before screening,&#xD;
             including, but are not limited to, myocardial infarction, severe or unstable angina,&#xD;
             coronary or peripheral artery bypass grafting, Heart failure NYHA grade Ⅲ or Ⅳ.&#xD;
&#xD;
          8. Left Ventricular Ejection Fractions (LVEF) &lt;50%.&#xD;
&#xD;
          9. Patient with a known active brain metastases.&#xD;
&#xD;
         10. Patient with a known myelodysplastic syndrome (MDS) or lymphoma.&#xD;
&#xD;
         11. Patient with a known active autoimmune disease, including , but are not limited to,&#xD;
             acquired or congenital immunodeficiency disease, allogeneic organ transplantation,&#xD;
             autoimmune hepatitis, systemic lupus erythematosus, inflammatory bowel disease.&#xD;
&#xD;
         12. Patient with a known active Hepatitis B or Hepatitis C.&#xD;
&#xD;
         13. Patient with a history of Human Immunodeficiency Virus (HIV) .&#xD;
&#xD;
         14. Patient with a history of syphilis.&#xD;
&#xD;
         15. Pregnant or lactating women.&#xD;
&#xD;
         16. Patient with a known active mental and neurological diseases.&#xD;
&#xD;
         17. The principal investigator judged that it is not suitable to participate in this&#xD;
             clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sa Wang, Master</last_name>
    <phone>8610-86464526-840</phone>
    <email>wangsa@corregene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yi Zhang, Doctor</last_name>
      <phone>0371-66295320</phone>
      <email>yizhang@zzu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Yi Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>3+3 dose escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

